
Opinion|Videos|August 16, 2024
Expert Perspective on the Expanding Treatment Landscape in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the expanding treament landscape for mCRPC.
Advertisement
Episodes in this series

Now Playing
- Given the evolution/expansion of the prostate cancer treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), can you discuss key factors that shape your treatment approach?
- How do patient characteristics such as age, performance status, and comorbidities influence that decision?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5



















